The distribution of immunoreactive surfactant-associated protein B (IR-SPB) was studied immunohistochemically in 120 subjects from 10 weeks of gestation to 7 postnatal months with a polydonal antibody against human SPB. Electron mia o m p y (EM) was done in 72 subjects to document the presence of Type II cells containing lamellar bodies. Fetuses of <18 weeks' gestation showed no immunostaining. Beginning at 18 weeks, non-mucous cells of tracheal glands immunestained in a few instances. Fetuses of 19 through 23 weeks showed progressive immunostaining of cells lining terminal airways. Infants 26-40 weeks who died with or without pulmonary pathology showed immunostaining of Type II cells and bronchioloalwolar (BA) portal cells ofthe respiratory bronchioles. In infants with hyaline membrane disease (HMD) who died <12 days after birth, occasional tracheal gland cells,
Introduction
Pulmonary surfactant is a complex mixture of lipids and associated proteins which is secreted into the terminal airway lumen where it lowers surface tension at the air-fluid interface. This remarkable property has dramatic effects on pulmonary mechanics. The presence, absence, and relative amounts of each of the components of the surfactant complex relate to lung function in health and disease and during the time sequence of lung development.
Two small molecular weight, highly hydrophobic proteins, SP-B and SP-C, have been obtained from organic solvent extracts of mammalian surfactants and have been associated with the surface tensionlowering properties of the lipid-protein mixture (1) (2) (3) (4) (5) (6) . SP-B is biosynthesized as a large protein of approximately 40 KD, which is cleaved proteolytically to yield a mature form of approximately 79 amino acids (7) .
The gene encoding human SP-B is approximately 9.5 KB and has been localized to chromosome 2 (8) . SP-B is present in isolated surfactant as a sulfhydryl-dependent dimer of 15-18 KD. Although Supported in part by HL 14214 and HL 28623.
it can be shown that both SP-B and SP-C promote phospholipid adsorption, only SP-B enriches the monolayer in disaturated phosphatidylcholine (9) (10) (11) (12) . Recent data suggest that SP-B resists surface tension by increasing the lateral stability of the phospholipid layer (13) .
There is evidence that the biophysical activities of the surfactantassociated proteins SP-A, SP-B, and SP-C complement each other which, in the case of SP-A and SP-B, may involve the organization of the highly structured lattice work of tubular myelin (14).
SP-B precursor protein has been identified in lung explant cultures of 18-and 23-week gestation human fetuses, and immunohistochemistry with the peptide antiserum localized this protein to granular inclusions in the apical region of Type 11-like epithelial cells (15) . Antiserum to a group of hydrophobic low molecular weight proteins, referred to as PSP-6, which most probably contains both SP-B and SP-C, has been used to immunostain adult human lung, localizing the protein within Type I1 alveolar epithelial cells and alveolar macrophages (16) . With in situ hybridization technique, a cDNA clone for PSP-B, also referred to as SP18 and SPUPhe), has been used to identify mRNA in Type I1 pneumocytes and in some cells of bronchioles in adult human lung (17) . An antibody to SP-B and SP-C has been used to examine lungs of premature infants with respiratory distress syndrome (RDS) and of more mature infants without RDS, showing a semiquantitative decrease in staining intensity in infants with RDS as compared with the more Results mature controls (18) .
This was a retrospective study of the distribution of the immunohistochemical signal for SP-B in human tracheal and pulmonary tissue obtained from normal human fetuses and from infants who died of both pulmonary and non-pulmonary causes in the first weeks and months of life. The purposes of this study were to describe the ontogeny of SP-B in these fetuses and to identify sites of SP-B immunostaining in the airways of infants who developed lung disease in early infancy.
Materials and Methods
Localization of immunoreactive hSP-B (IR-hSP-B) was carried out using the peroxidase-anti-peroxidase (PAP) method. All sections were independently evaluated by two of the authors (MS and MG) with agreement as to interpretation. Tracheas were not available for every subject, and bronchi and associated glands were not always present in available lung sections.
A number of non-pulmonary tissues were examined immunohistochemically for hSP-B, including esophagus, stomach, duodenum including Brunner's glands, jejunum, large intestine, kidney, liver, pancreas, uterus. cervix, bone marrow, spleen, thyroid, skin, and eccrine sweat glands. None of these non-pulmonary tissues immunostained for hSP-B.
Antiserum. Rabbit antiserum, anti-hSP-B, was generated against a synthetic human SP-B peptide sequence comprised of 78 amino acids, amino terminus Phe-Pro-lle-Pro, etc. The antiserum is strongly reactive with native and synthetic human SP-B and proSP-B (19) . Anti-hSP-B is unreactive with purified SP-C or the SP-C precursor, as assessed by ELISA assay, Western blot analysis, or after immunoprecipitation of radiolabeled cells expressing rat or human SP-C (20).
Immunohistochemistry. Tissues were fixed in 10% phosphate-buffered formalin (pH 7.2) and embedded in paraffin. Sections were cut at 3 pm and mounted on alkylsilane-coated slides. The PAP method of Sternberger (21) was used. Sections were deparaffinized, hydrated, treated with 0.3% hydrogen peroxide in methanol, and exposed to 10% normal swine serum to eliminate nonspecific staining. The primary antibody at an appropriate dilution was applied and allowed to remain overnight at room temperature. After washing, sections were exposed to a swine antiserum to rabbit immunoglobulin, washed again, and treated with horseradish peroxidase coupled to rabbit anti-peroxidase. The peroxidase activity was then localized by reaction with a solution containing 0.05 % 3,3'-diaminobenzidine and 0.01% hydrogen peroxide and counterstained with hematoxylin.
Specificity of immunohistochemical results was tested by exposing adjacent tissue sections to non-immune rabbit serum in place of the primary antiserum. Tissues known to contain or not to contain the antigen were used as controls.
Electron Microscopy. Lung tissue (l-mm3 blocks) for electron microscopy (EM) was taken within 2 hr after death from areas immediately adjacent to tissues fixed for light microscopy. They were fixed by immersion in 2.5% glutaraldehyde in phosphate buffer (pH 7.2). After rinsing in 7.5% sucrose in phosphate buffer (pH 7.3-7.4). tissues were fixed in Millonig's osmium tetroxide (22) for 2 hr, dehydrated by Luft's procedure (23), and embedded in araldite (Ladd Research Industries; Burlington, VT) or Spurr (Ted Pella; Redding, CA). Semi-thin sections stained with toluidine blue were examined by light microscopy and representative fields selected for thin sectioning. Thin sections were cut with a diamond knife on an LKB uluatome, mounted on uncoated copper mesh grids, and doubly stained with uranyl acetate and lead citrate (24). Observations were made on a Philips 300 electron microscope.
Lung tissue was available from 120 subjects (40 fetuses and 80 infants) ranging in developmental age from 10-42 post-conceptional weeks and in postnatal age from stillborn to death at 7 months. Tracheal tissue was also available from 16 fetuses and from 27 liveborn infants. Fetal tissue was obtained at the time of hysterotomy or hysterectomy abortion, or from stillborn fetuses known to be alive during labor. These tissues were obtained with parental consent and these studies were approved by the Committee for the Protection of Human Subjects of Vanderbilt University Medical Center. Many of the more mature fetuses were delivered by prostaglandin abortion for a variety of indications, frequently for premature rupture of the membranes (PROM). Tissue from live-born infants was obtained post mortem at lung biopsy or at autopsy. In three instances tissue was obtained from living infants undergoing lobectomy. Transmission EM from 72 of these subjects was used to correlate the presence of terminal airway cells containing lamellar bodies with cells immunostaining for hSP-B.
We have divided the patient population into "normal fetuses" and live-born infants dying with and without primary lung disease. The majority of these infants had hyaline membrane disease (HMD) or its sequelae.
We recognize that there is a lack of consensus in the literature as to the nomenclature of non-ciliated, non-mucous-producing cells in conducting airways in the entire respiratory tract (25) (26) (27) (28) . For the purpose of this discussion, we have used the term Clara cell to identify those non-ciliated epithelial cells in ciliated conducting airways which are neither basal cells, goblet cells, nor neuroendocrine cells and are considered to have a secretory function. We have, however, not referred to the cuboidal cells lining the nonciliated respiratory bronchioles as Clara cells. These cells we have labeled respiratory bronchiolar and bronchioloalveolar (BA) portal cells (259, considering respiratory bronchiolar cells as differentiated and BA portal cells as only partially differentiated precursor cells for respiratory bronchiolar cells, mature Type I1 alveolar cells and, by further differentiation, also for Type I alveolar cells (30) .
Fetuses
Lungs of the 40 fetuses and tracheas of 16 of these fetuses were stained for IR-hSP-B ( Table 1) . Lightly immunostained tracheal epithelial cells were found in only one fetus of 23 weeks in the depths of tracheal folds, and in five fetuses a few non-mucous cells of tracheal glands were positive ( Figure 1 ). Only after 19 weeks of gestation did terminal airway cuboidal lining cells begin to immunostain for hSP-B with regularity, and this corresponded with the timing of the appearance of lamellar bodies in these same sites in the electron micrographs (Figures 2a and 2b) . In seven fetuses these findings were associated with a history of PROM, suggesting the possibility of acceleration of terminal airway maturation under these circumstances (Figures 3a and 3b ). In four additional fetuses, although PROM was not documented, polymorphonuclear leukocytes were present in some airways, never in great numbers, but were suggestive of amnionitis, which may also have accounted for acceleration of pulmonary maturational events. Bronchial glands were largely undifferentiated until 18 weeks of gestation. However, Table 1 
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Infants Dying with Non-pulmonary Pathology
Fourteen infants between 25 and 42 weeks of gestation dying with non-pulmonary pathology were examined ('kble 2). Only five tracheas were available, and none showed immunostaining of epithelium or glands for hSPB. Non-ciliated epithelial cells (Clara cells) of bronchi and a few non-mucous cells of the bronchial glands were positive for IR-hSP-B in one 38-week infant, and Clara cells were also immunostained in ciliated bronchioles in this infant and in an additional infant (Figure 4 ). All 14 infants showed positive immunostaining of cells of the BA portals and /or mature Type I1 cells (Figure 5) . Most infants over 36 weeks of gestation had positive luminal material and all six on whom EM was available showed lamellar bodies in Type I1 cells. Positively staining macrophages were present in the four infants over 90 hr of age at the time of death. in two 22-week fetuses with PROM and terminal airway epithelial immunostaining, non-mucus cells of bronchial glands were also immunostained for hSP-B. Neither macrophages nor immunostained luminal material were seen in any of these fetuses. In 37 of 40 fetuses on whom EM was available, the timing and appearance of lamellar bodies correlated well with IR-hSP-B in terminal airway epithelium.
Infants Dying with Pdmonary Pathology, non-HMD
Thirteen infants died with pulmonary pathology unrelated to HMD ( Table 3 ). Most of these infants had sepsis associated with PROM or Group B B-hemolytic streptococcal sepsis. In two infants there was immunostaining of a few non-mucous cells of tracheal glands. All infants had either positive BA portal cells, mature Type I1 cells, or cells relining terminal airways. Only two had positively stained macrophages and five had stained luminal material. Lamellar bodies correlated well with immunostained cells in terminal airways in all six instances where EM was available. Immunostaining for hSP-B was frequently absent in areas of sections where widespread hemorrhage, infection, or edema were present or with alveolar collapse.
Infants Dying with Hyaline Membrane Disease (Birth Through 11 Days)
Thirty-two newborn infants died with HMD at less than 11 days after birth ( Table 4 ). Of the 11 available tracheas, two had immunostaining of rare epithelial cells but six had immunostaining of non-mucous tracheal gland cells for hSP-B. Cells in bronchial epithelium were immunostained in three infants, but none in bronchial glands. Five had positive Clara cells in ciliated bronchioles ( Figure 6 ) and 17 had positive BA portal cells. Most had Type I1 cells or cells relining terminal airways positively immunostained (Figure 7) . In HMD infants with Type I1 cells, most of these cells were undergoing slough and necrolysis in the early hours of the disease process. All infants with cells relining terminal airways were over 24 hr old at the time of death. This time corresponds to the appearance of migrating cells relining denuded areas of the respiratory bronchioles and terminal airways after cell slough and hyaline membrane formation on the basement membrane. In the presence of alveolar hemorrhage, edema, and/or collapse, immunostaining for hSP-B was rarely seen. Five infants over 45 hr old at death had immunostained macrophages ( Figure 8 ), and many had positive luminal material. Fifteen of 18 infants on whom EM was available had Type I1 cells containing lamellar bodies (Figures 9a and 9b ). 
Infants Dying with Bronchopulmonary Dysplasia
Tissue was available from 18 infants dying between 12 days and 7 postnatal months classified as BPD at autopsy ( Table 5 ) . Lung sections from three additional infants were obtained from lobectomy specimens at 28 and 30 days and at 4.8 months. Four of the seven infants with tracheal tissue had a few immunostained nonmucous cells of tracheal glands. Only two bronchi of 12 had epithelial cells immunostained for hSP-B, and one of these also had immunostained bronchial gland cells. Three infants had immunostained Clara cells in ciliated bronchioles ( Figure 10 ). Eleven infants had immunostained BA portal cells. In 14 infants, either phenotypic Type I1 cells or dysplastic cells relining terminal airways which immunostained for hSP-B correlated with the presence of lamellar bodies on EM in a phenotypic variety of dysplastic cells ( Figures Ila, Ilb, 12a, and 12b ). Most of the BPD infants had immunostained macrophages and luminal material.
Discussion
The study we report here describes the pattern of occurrence of cells immunoreactive for human SP-B in the developing respiratory system of human fetuses and in that of neonates dying with and without lung disease. The respiratory tract develops from cephalad to caudad. Tracheal epithelial cells are differentiating into ciliated cells and goblet cells by about 13 weeks of gestation, and although buds of tracheal glands are present at that time they do not differentiate into true acini with mucous and undifferentiated cells until around 18 weeks of gestation (3132). Immunoreactivity of tracheal epithelium for hSP-B was seen rarely and, when seen in either fetuses or live-born infants, consisted of a few cells localized near the origin of gland ducts. Between 18-23 weeks we began to find a few non-mucous cells of the submucosal glands immunostained for hSP-B. The differentiation of glandular serous cells is a late fetal event, at about 26 weeks of gestation. Putative intrapulmonary bronchial glands appear by 13 weeks of gestation, but typical acinar structures do not differentiate until 24-25 weeks of gestation in the more proximal bronchi, continuing to differentiate more distally until term (31.33). In fetuses, immunoreactivity for hSP-B in bronchial epithelium was never observed, but a few immunoreactive cells appeared in bronchial glands in two 22-week fetuses.
The ciliated lining cells of bronchioles appear to be committed as early as 15 weeks of gestation, but in fetuses of this age bronchiolar cells were never immunostained. Terminal airways continue to be lined with glycogen-filled undifferentiated cells until capil- Table 3 lary invasion begins at around 19-20 weeks of gestation (32). It was around this gestational age that terminal airway lining cells first appeared immunoreactive for hSP-B. With the development of saccules and an air-blood interface, immunoreactivity for hSP-B was observed in BA portal cells and mature Type I1 cells.
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The exact timing of the appearance of IR-hSP-B and of lamellar bodies in the terminal airway lining cells appears to vary with many of the circumstances which are associated with pre-term delivery, one of the most common of which is PROM. There is increasing evidence to support the hypothesis that in many if not most pregnancies associated with PROM, infection of extra-embryonic tissues or uterine decidua is the antecedent event that leads to premature parturition (34). It is now believed that the products of microorganisms (e.g., bacterial endotoxin) act on macrophages or monocytes of uterine decidua to cause the biosynthesis and outpouring of cytokines and prostaglandins that serves to provoke preterm labor (35,36) . The findings of early immunostaining of cells for hSP-B lining terminal airways, lamellar bodies on EM, and a history of PROM, or the finding of a few polymorphonuclear leukocytes in fetal airways are therefore not surprising. The documentation of PROM in seven fetuses of 19 through 23 weeks of gestation and of d a t i o n in another four in the same age group correlated with the appearance of immunostaining of distal airway cells in nine of these 11 fetuses. Of eight infants with non-HMD who died with pulmonary pathology between 2 3 and 32 weeks, there were six documented cases of PROM and infection in six, of which five overlapped. In contrast, only two of the 14 infants dying with nonpulmonary pathology had PROM, and neither showed evidence of airway infection. The common occurrence of these factors attests to their importance in pre-term delivery and its adverse outcome.
The presence of terminal airway cells immunoreactive for hSP-B in infants with early HMD is surprising, as HMD is associated physiologically with the effects of surfactant insufficiency. The presence of Type I1 cells or of relining Type I1 cells and their correlation with lamellar bodies on EM was related more to length of survival than to gestational age. The rapidity with which terminal airways were relined with new migrating Type 11 cell precursors, presumably arising from the BA portals, was impressive in the healing process. By the time HMD infants were 3 days or older, regardless of their length of survival or gestational age, Type I1 cells or relining Type I1 cells immunostaining for hSP-B were uniformly present, as were lamellar bodies on EM. Immunostained luminal material and the presence of macrophages became common as the healing process became chronic with BPD.
The appearance of cells immunoreactive for hSP-B lining regenerating airways, which include terminal conducting airways and the most distal airways present in infants with progressive BPD, implies the potential of these cells, which are often dysplastic in phenotype, to produce surfactant-associated proteins and possibly surfaceactive phospholipids. Whether these proteins or lipids maintain normal function is not known, as some airways lined with these cells are open, but many are obliterated or collapsed and fail to immunostain for hSP-B. The appearance of many macrophages in open airways of BPD infants, in association with abundant luminal material immunostaining for surfactant-associated proteins, suggests that these dysplastic lining cells no longer have the ability to recycle secreted surfactant or its apoproteins (37-40) and that macrophages become the principal mechanism for the removal of surfactant and its apoproteins from the airways.
The cells of bronchioles were never immunostained in the fetuses studied. However, in every other category of newborn infant studied, rare immunostained Clara cells in ciliated bronchioles were identified. Although the conducting airways of mice are morphologically considerably different from those of humans, areas analogous to human bronchioles can be shown to have increasing immunostaining for SP-B after the animals are exposed to a high-oxygen environment for several days (41). The first evidence of induction occurs within 24 hr. Many of the infants described in these studies were treated, often for many days, with high-oxygen environments thought necessary for survival. This might account for the appearance of IR-hSP-B in Clara cells and BA portal cells before relining Type I1 cells became fully differentiated in some of these infants.
Perhaps the most unexpected finding in the present study was the appearance of IR-hSP-B in cells other than those of the distal airways, including epithelial lining cells and non-mucous gland cells of the trachea and bronchi. Clara cells in bronchioles have been described previously as sites for SP-B localization (17) . When immunostained cells appear in the respiratory bronchioles at the bron-chioloalveolar portals, it can be speculated that they act as precursor cells for Type I1 alveolar cells, especially important in times of widespread cell destruction in these areas, such as occurs in acute HMD. The same role would be difficult to imagine for epithelial cells in more proximal conducting airways such as those of bronchi, larger bronchioles, and tracheal or bronchial glands. It is possible, however, that the ability of SP-B to enhance spreading of liquids on cell membrane surfaces might be utilized in conducting airways as the mucous blanket is moved up the tracheobronchial tree by cilia. At the present time such a role remains speculative (42).
